Biosimilar Red Tape Elimination Act
- Sponsor
- Rep. Pfluger, August [R-TX-11]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Sep 19, 2025
Bottom line
The bill aims to accelerate patient access to lower-cost biosimilar medications by removing a significant regulatory hurdle for interchangeability, potentially increasing competition in the biologics market and reducing healthcare costs.
What it actually does
This bill, the "Biosimilar Red Tape Elimination Act," streamlines the approval process for interchangeable biosimilar biological products by automatically deeming all biosimilars licensed under section 351(k) of the Public Health Service Act as interchangeable with their reference product. It eliminates the separate regulatory pathway and additional data requirements previously needed to demonstrate interchangeability, while preserving existing exclusivity periods for products already on the market. The bill also mandates the FDA to update its guidance documents to reflect these changes.
Proponents argue
Proponents argue that the current separate interchangeability designation process creates unnecessary delays and costs for biosimilar manufacturers, hindering market competition and patient access to more affordable treatments. They contend that the scientific standards for biosimilarity are already rigorous enough to ensure safety and efficacy, making a distinct interchangeability designation redundant and burdensome. This bill would reduce "red tape" and foster a more robust biosimilar market, ultimately benefiting patients and payers.
Opponents contend
Some might argue that removing the separate interchangeability pathway could compromise patient safety by allowing automatic substitution without the additional clinical data previously required to demonstrate that switching between a reference product and a biosimilar has no adverse impact. They might also raise concerns about potential impacts on innovation for novel biologics if the market for biosimilars becomes too aggressive too quickly, potentially reducing incentives for original drug development.
The bill is short and relatively straightforward for those familiar with pharmaceutical regulation, allowing for quick comprehension of its core changes and implications.
Section 2(a)(1), (2), (3), (4) of the bill, amending 42 U.S.C. 262(k)
Automatic Interchangeability Designation for Biosimilars
This provision amends the Public Health Service Act to remove the requirement for a separate determination of interchangeability for biosimilar biological products. Instead, any biological product licensed as biosimilar to a reference product will automatically be deemed interchangeable with that reference product. This eliminates the need for additional clinical studies often required to demonstrate interchangeability, streamlining the approval process for biosimilars.
Supporters argue
Supporters argue this will accelerate the availability of more affordable biosimilars, driving down healthcare costs and increasing patient access. They believe the existing biosimilarity standard is sufficient to ensure safety and efficacy for substitution, making a distinct interchangeability designation redundant and costly.
Critics contend
Some might argue that removing the separate interchangeability pathway could reduce the incentive for manufacturers to conduct additional studies that specifically demonstrate safe and effective switching, potentially raising concerns about patient confidence or unforeseen clinical outcomes, though the bill's proponents would counter that the biosimilarity standard is robust enough.
Tradeoffs
This provision balances the desire for faster market entry and cost reduction against the previous regulatory emphasis on additional data for interchangeability to provide an extra layer of clinical assurance for safe switching between products.
Section 2(a)(4)(B), (a)(5) of the bill, amending 42 U.S.C. 262(k)
Preservation of Existing First Interchangeable Exclusivity
This provision ensures that any unexpired period of "first interchangeable exclusivity" granted under the law *before* the enactment of this Act will remain in effect. This means that biosimilars that previously obtained this exclusivity will retain their market protection for the duration of that period, even though the new law eliminates the concept for future products. This provides a transitional safeguard for early market entrants under the old rules.
Section 2(c)
FDA Guidance Revision Mandate
This section mandates that the Secretary of Health and Human Services (acting through the FDA) update existing draft and final guidance documents within 18 months to reflect the changes made by this Act. Specifically, it requires revising or revoking guidance related to demonstrating interchangeability and issuing new or revised guidance on the data needed for biosimilar approval under the new framework. This ensures regulatory clarity for industry.